Skip to main content
Clinical Trials/IRCT20110807007244N8
IRCT20110807007244N8
Recruiting
Phase 2

Comparison prognosis the effect of two methods surfactant administration: Minimally invasive surfactant therapy(MIST) versus InSurE (Intubate, surfactant administration and extubate) in preterm neonates with respiratory distress syndrome at two year

Mashhad University of Medical Sciences0 sites148 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Respiratory distress syndrome of newborn.
Sponsor
Mashhad University of Medical Sciences
Enrollment
148
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Premature infants with respiratory distress syndrome with a gestational age of 26 to 34 weeks require surfactant

Exclusion Criteria

  • Congenital anomaly
  • Requires mechanical ventilation in the delivery room
  • Congenital infection
  • Congenital heart disease
  • History of developmental delay

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Comparison of two methods of respiratory support in neonates
IRCT20190416043290N2Tehran University of Medical Sciences78
Completed
Not Applicable
To check fit of upper denture and its effect on palatal tissue using two methods to establish seal in completely edentulous patients
CTRI/2021/04/032679Dr Riddhi Lalan17
Completed
Not Applicable
Comparison of the Effect of Oral Presentation and Hospital Tour on Mothers' Anxiety before the Children's Open Heart SurgeryAnxiety.Anxiety disorder, unspecified
IRCT20190130042557N1Shahid Beheshti University of Medical Sciences96
Active, not recruiting
Not Applicable
Estudio comparativo de dos métodos para predecir el uso de co-receptores por el virus de la inmunodeficiencia 1 (HIV-1): el ensayo fenotípico (Trofile ESTA®) y la respuesta virológica a corto plazo a un antagonista de CCR5.Infección por el Virus de la Inmunodeficiencia Humana tipo-1 (VIH-1).El antirretroviral maraviroc pertenece a un grupo de medicamentos llamados antagonistas del CCR5 e impide la entrada del VIH-1 en las células sanguíneas, bloqueando el receptor CCR5 que el VIH utiliza para poder entrar en estas células.
EUCTR2008-007208-28-ESAsociación para el Estudio de las Enfermedades Infecciosas
Completed
Not Applicable
The effect of two methods, compression massage and ice massage in LI4 and SP6 points on pain after appendectomyPain after appendectomy.Symptoms and signs involving cognition, perception, emotional state and behaviourR40-R46
IRCT20170921036302N2Sabzevar University of Medical Sciences90